Intussusception after Rotavirus Vaccine Introduction in India
Open Access
- 12 November 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 383 (20), 1932-1940
- https://doi.org/10.1056/nejmoa2002276
Abstract
A three-dose, oral rotavirus vaccine (Rotavac) was introduced in the universal immunization program in India in 2016. A prelicensure trial involving 6799 infants was not large enough to detect a small increased risk of intussusception. Postmarketing surveillance data would be useful in assessing whether the risk of intussusception would be similar to the risk seen with different rotavirus vaccines used in other countries. We conducted a multicenter, hospital-based, active surveillance study at 27 hospitals in India. Infants meeting the Brighton level 1 criteria of radiologic or surgical confirmation of intussusception were enrolled, and rotavirus vaccination was ascertained by means of vaccination records. The relative incidence (incidence during the risk window vs. all other times) of intussusception among infants 28 to 365 days of age within risk windows of 1 to 7 days, 8 to 21 days, and 1 to 21 days after vaccination was evaluated by means of a self-controlled case-series analysis. For a subgroup of patients, a matched case–control analysis was performed, with matching for age, sex, and location. From April 2016 through June 2019, a total of 970 infants with intussusception were enrolled, and 589 infants who were 28 to 365 days of age were included in the self-controlled case-series analysis. The relative incidence of intussusception after the first dose was 0.83 (95% confidence interval [CI], 0.00 to 3.00) in the 1-to-7-day risk window and 0.35 (95% CI, 0.00 to 1.09) in the 8-to-21-day risk window. Similar results were observed after the second dose (relative incidence, 0.86 [95% CI, 0.20 to 2.15] and 1.23 [95% CI, 0.60 to 2.10] in the respective risk windows) and after the third dose (relative incidence, 1.65 [95% CI, 0.82 to 2.64] and 1.08 [95% CI, 0.69 to 1.73], respectively). No increase in intussusception risk was found in the case–control analysis. The rotavirus vaccine produced in India that we evaluated was not associated with intussusception in Indian infants. (Funded by the Bill and Melinda Gates Foundation and others.)Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1165083)
- Centers for Disease Control and Prevention (MOA#871-15SC)
- Fogarty International Center (D43 TW0007392)
This publication has 31 references indexed in Scilit:
- Rotavirus vaccine impact assessment surveillance in India: protocol and methodsBMJ Open, 2019
- Intussusception and Monovalent Rotavirus Vaccination in Singapore: Self-Controlled Case Series and Risk-Benefit StudyThe Journal of Pediatrics, 2015
- Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trialThe Lancet, 2014
- Population‐Based Incidence of Intussusception and a Case‐Control Study to Examine the Association of Intussusception with Natural Rotavirus Infection among Indian ChildrenThe Journal of Infectious Diseases, 2009
- The methodology of self-controlled case series studiesStatistical Methods in Medical Research, 2009
- Sample sizes for self-controlled case series studiesStatistics in Medicine, 2006
- Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus VaccineThe New England Journal of Medicine, 2006
- Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus GastroenteritisThe New England Journal of Medicine, 2006
- Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentationVaccine, 2003
- Protection Conferred by Neonatal Rotavirus Infection against Subsequent Rotavirus DiarrheaThe Journal of Infectious Diseases, 1993